StockViz
Share URL
Embed chart view
-
Export .csv
-
Download image
-
Copy link
-
Embed code
StockViz
RANKINGS
Novartis AG
Swiss Stock Exchange:NOVN.SW
Sector
Industries
Location
Market Cap
USD 242.32 B
Share Price
USD 122.69
Avg Daily Volume
3,462,718
Change (1 day)
0.10%
Change (1 year)
13.54%
Change (YTD)
25.09%
Novartis AG Operating Cash Flow for the year ending December 31, 2024: USD 17.62 B
Novartis AG Operating Cash Flow is USD 17.62 B for the year ending December 31, 2024, a 21.86% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
-
Novartis AG Operating Cash Flow for the year ending December 31, 2023 was USD 14.46 B, a 1.56% change year over year.
-
Novartis AG Operating Cash Flow for the year ending December 31, 2022 was USD 14.24 B, a -5.54% change year over year.
-
Novartis AG Operating Cash Flow for the year ending December 31, 2021 was USD 15.07 B, a 10.41% change year over year.
-
Novartis AG Operating Cash Flow for the year ending December 31, 2020 was USD 13.65 B, a 0.18% change year over year.
Competitors
AbbVie Inc.
USD 190.62
ABBV
+0.85
0.45%
Novo Nordisk A/S
USD 69.43
NOVO-B.CO
-1.17
-1.65%
Roche Holding AG
USD 347.13
RO.SW
+4.68
1.37%
Abbott Laboratories
USD 133.22
ABT
-0.14
-0.10%
AstraZeneca PLC
USD 140.76
AZN.L
+0.34
0.24%
Merck & Co., Inc.
USD 83.71
MRK
+2.34
2.88%
Amgen Inc.
USD 296.52
AMGN
-0.48
-0.16%
Pfizer Inc.
USD 25.56
PFE
-0.06
-0.23%
Gilead Sciences, Inc.
USD 113.24
GILD
+2.18
1.96%
Sanofi
USD 97.65
SAN.PA
-0.05
-0.05%
Vertex Pharmaceuticals Incorporated
USD 478.96
VRTX
+12.60
2.70%
Bristol-Myers Squibb Company
USD 47.66
BMY
+0.62
1.32%
GSK plc
USD 19.36
GSK.L
+0.16
0.81%
CSL Limited
USD 159.25
CSL.AX
-1.34
-0.84%
Chugai Pharmaceutical Co., Ltd.
USD 46.51
4519.T
-0.57
-1.20%
Regeneron Pharmaceuticals, Inc.
USD 552.58
REGN
+4.83
0.88%
MERCK Kommanditgesellschaft auf Aktien
USD 130.44
MRK.DE
-0.41
-0.31%
Jiangsu Hengrui Medicine Co., Ltd.
USD 7.96
600276.SS
+0.52
7.00%
Takeda Pharmaceutical Company Limited
USD 30.27
4502.T
+0.31
1.03%
Alnylam Pharmaceuticals, Inc.
USD 320.87
ALNY
+3.37
1.06%
Key Data
| Date | Operating Cash Flow | Capital Expenditure | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
Competitors
AbbVie Inc.
USD 190.62
ABBV
+0.85
0.45%
Novo Nordisk A/S
USD 69.43
NOVO-B.CO
-1.17
-1.65%
Roche Holding AG
USD 347.13
RO.SW
+4.68
1.37%
Abbott Laboratories
USD 133.22
ABT
-0.14
-0.10%
AstraZeneca PLC
USD 140.76
AZN.L
+0.34
0.24%
Merck & Co., Inc.
USD 83.71
MRK
+2.34
2.88%
Amgen Inc.
USD 296.52
AMGN
-0.48
-0.16%
Pfizer Inc.
USD 25.56
PFE
-0.06
-0.23%
Gilead Sciences, Inc.
USD 113.24
GILD
+2.18
1.96%
Sanofi
USD 97.65
SAN.PA
-0.05
-0.05%
Vertex Pharmaceuticals Incorporated
USD 478.96
VRTX
+12.60
2.70%
Bristol-Myers Squibb Company
USD 47.66
BMY
+0.62
1.32%
GSK plc
USD 19.36
GSK.L
+0.16
0.81%
CSL Limited
USD 159.25
CSL.AX
-1.34
-0.84%
Chugai Pharmaceutical Co., Ltd.
USD 46.51
4519.T
-0.57
-1.20%
Regeneron Pharmaceuticals, Inc.
USD 552.58
REGN
+4.83
0.88%
MERCK Kommanditgesellschaft auf Aktien
USD 130.44
MRK.DE
-0.41
-0.31%
Jiangsu Hengrui Medicine Co., Ltd.
USD 7.96
600276.SS
+0.52
7.00%
Takeda Pharmaceutical Company Limited
USD 30.27
4502.T
+0.31
1.03%
Alnylam Pharmaceuticals, Inc.
USD 320.87
ALNY
+3.37
1.06%